Reactions 1680, p74 - 2 Dec 2017 Hepatitis B reactivation syndrome: case report A 45-year-old woman developed hepatitis B reactivation syndrome following treatment with busulfan and cyclophosphamide [dosages, routes and time to reaction onset not stated]. The woman was diagnosed with Durie-Salmon Stage II International Staging System II multiple myeloma, in June 1998. She received an allograft transplant in December 1998. Subsequently, she received conditioning therapy with busulfan, cyclophosphamide and total bone marrow irradiation. Post-transplant and the busulfan and cyclophosphamide immunosuppressant therapy, she developed hepatitis B reactivation syndrome. The woman was treated successfully with lamivudine. She developed recurrent extra-medullary plasmacytomas in the breast and right atrium of the heart 11 years and 13 years after the allograft transplant, respectively. Author comment: "The posttransplant course was rather uneventful except for a hepatitis B reactivation syndrome (after immunosuppressant therapy) successfully treated with lamivudine." Stawis AN, et al. Recurrent plasmacytomas after allografting in a patient with multiple myeloma. Case Reports in Medicine 2012: 2012. Available from: URL: http://doi.org/10.1155/2012/168785 - USA 803284649 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera